IMS 2023 | Post-induction undetectable MRD ameliorates the high risk determined by FISH among NDMM
Guldane Cengiz Seval, MD, Ankara University School of Medicine, Ankara, Turkey, discusses a study exploring the role of measurable residual disease (MRD) in the context of cytogenetic risk in patients with newly diagnosed multiple myeloma (NDMM) who underwent autologous stem cell transplantation (autoSCT). Dr Cengiz Seval gives an overview of the cytogenetic profile of the patients enrolled in this study, and further highlights the results, which demonstrate that post-induction MRD is correlated with progression-free survival (PFS) and that achieving post-induction MRD negativity may ameliorate the high risk determined by FISH in this patient population. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
